U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07322068) titled 'Perennial Malaria Chemoprevention in the Malaria Vaccine Era' on Jan. 05.
Brief Summary: Malaria remains a major cause of pediatric deaths and morbidity in Africa. An affordable malaria vaccine, R21, is being deployed in Uganda and other African countries with high malaria transmission, but efficacy is incomplete and wanes rapidly, and R21 does not provide protection until infants complete the primary vaccination series, or ~9 months of age. The goal of this study is to see whether combining R21 vaccination with two novel perennial malaria chemoprevention regimens can enhance protection against malaria compared with R21 alone. This s...